October 18, 2016 - For patients with chronic back pain, "open" treatment with placebo--informing patients that they are taking an inactive pill, and why it might be helpful--leads to reductions in pain and disability, reports a study in PAIN®, the official publication of the International Association for the Study of Pain (IASP). The journal is published by Wolters Kluwer.
"This study is the first to demonstrate potential clinically significant benefits of open placebo treatment in chronic low back pain," according to the new research by Claudia Carvalho, PhD, of ISPA-Instituto Universitário, Lisbon, and colleagues. "Our data suggests that harnessing placebo effects without deception is possible in the context of a plausible rationale."
Better Improvement When Open Placebo Is Added to Pain Medications
The study included 97 adult patients with low back pain lasting at least three months. Patients were randomly assigned to three weeks of treatment on their usual pain medications alone, or on their usual medications plus placebo.
But unlike the usual "placebo-controlled" study, patients knew they were taking a placebo. The researchers explained to patients about the "potentially powerful" placebo effect, and how the body may automatically respond to placebo treatments. Previous studies have suggested that placebos can have "clinically meaningful benefits"--possibly reflecting "non-conscious processes" related to participating in a study and taking pills.
Measures of back pain and disability were compared between groups. After three weeks, patients initially assigned to usual treatment were offered the chance to take placebo pills. Eighty-three patients completed the study.
The results showed greater reductions in pain for patients assigned to placebo. On a 0-to-10 scale, patients in the placebo group had a 1.5-point improvement in pain score, compared to no significant change for patients taking usual medications only. The placebo group also had nearly a three-point reduction in back pain-related disability score, compared to no change for the usual-treatment group.
Overall, open placebo treatment reduced initial pain and disability scores by approximately 30 percent. Patients in the usual-treatment group had similar improvements after they started taking placebo pills. There were no adverse effects in either group.
There's a pressing need for more effective treatments for low back pain, which causes more disability worldwide than any other medical condition. Conventional "double-blind" trials often find commonly prescribed treatments for back pain are no more effective than inactive placebos.
Could the placebo effect be used to improve treatment of back pain? Giving placebo pills in open fashion--including explanations of how the placebo effect may work--offers a way to overcome the ethical conflict of deceiving patients that they are taking an active medication.
The researchers acknowledge some limitations of their study, particularly its small size and short duration. They also note that it was advertised as a "mind-body clinical study," which might have attracted patients who are concerned about conventional medicine or attracted to complementary and alternative treatments.
"Our data suggest that open-label placebo can be a safe and effective adjunct to treatment for chronic low back pain," Dr. Carvalho and coauthors conclude. They call for further studies evaluating the potential for "harnessing placebo effects without deception," for back pain as well as other conditions.
###
Article: "Open-label placebo treatment in chronic low back pain: a randomized controlled trial" (doi: 10.1097/j.pain.0000000000000700)
About PAIN
PAIN is IASP's official journal. Published monthly, PAIN presents original research on the nature, mechanisms, and treatment of pain. Available to IASP members as a membership benefit, this peer-reviewed journal provides a forum for the dissemination of multidisciplinary research in the basic and clinical sciences. It is cited in Current Contents and Index Medicus.
About the International Association for the Study of Pain
IASP is the leading professional organization for science, practice, and education in the field of pain. Membership is open to all professionals involved in research, diagnosis, or treatment of pain. IASP has more than 7,000 members in 133 countries, 90 national chapters, and 20 special interest groups (SIGs). IASP brings together scientists, clinicians, health-care providers, and policymakers to stimulate and support the study of pain and translate that knowledge into improved pain relief worldwide.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit http://www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.
Journal
Pain